Our mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil.
We are very pleased to be able to bring Suprax® an important anti-infective product in pediatric practice, back to the US market.
We are recognized as a leading manufacturer of cephalosporin API's, with FDA approval to manufacture complex oral and injectable cephalosporins.
Lupin is amongst the world's largest manufacturers of products in its chosen therapeutic areas.
Lupin launches Generic Trilipix® Delayed - Release Capsules 45 mg & 135 mg in the US
Lupin launches Generic Aciphex® Delayed-Release Tablets, 20 mg in the US
Lupin Receives FDA Approval for its New Drug Application for Antara® Capsules
Lupin launches Generic ZYMAXID™ Ophthalmic solution in the US
Lupin Receives FDA Approval for Generic Ambien CR® Extended-release Tablets
Lupin receives FDA Approval for Generic Ranexa® Extended-release Tablets
manufacturing / r&d
Copyright © 2010, Lupin Pharmaceuticals, Inc., All Rights Reserved.
Created and Designed by